A diagnostic formulation is provided comprising a tropane having a radioactive concentration of at least 1.6 mCi/mL at least about 51 hours post creation. The diagnostic formulation optionally comprises a radiolabeled dopamine transporter (DAT) ligand useful in the diagnosis of Parkinson's disease (PS). One example of a radiolabeled dopamine transporter (DAT) ligand example is [.sup.123I]-2β-carbomethoxy-3β-(4-flurophenyl)-N-(3-iodo-E-allyl) nortropane.

Fluoridated organofluoroborates comprising at least one .sup.18F atom and precursors thereto, for use in PET scanning.

Fluoridated organofluoroborates comprising at least one .sup.18F atom and precursors thereto, for use in PET scanning.

Provided herein are compounds useful for binding to one or more histone deacetylase enzymes (HDACs). The present application further provides radiolabeled compounds useful as a radiotracer for position emission tomography imaging of HDAC. Methods for prepared unlabeled and labeled compounds, diagnostic methods, and methods of treating diseases associated HDAC are also provided.

The present invention provides a method for the generation of .sup.223Ra of pharmaceutically tolerable purity comprising i) preparing a generator mixture comprising .sup.227Ac, .sup.227Th and .sup.223Ra; ii) loading said generator mixture onto a strong base anion exchange resin; iii) eluting said .sup.223Ra from said strong base anion exchange resin using a first mineral acid in an alcoholic aqueous solution to give a first eluted .sup.223Ra solution; iv) loading the .sup.223Ra of the first eluted .sup.223Ra solution onto a strong acid cation exchange resin; and v) eluting the .sup.223Ra from said strong acid cation exchange resin using a second mineral acid in aqueous solution to provide a second eluted solution. The invention additionally provides products of corresponding purity and/or products obtained or obtainable by such a method.

The present invention provides a method for the generation of .sup.223Ra of pharmaceutically tolerable purity comprising i) preparing a generator mixture comprising .sup.227Ac, .sup.227Th and .sup.223Ra; ii) loading said generator mixture onto a strong base anion exchange resin; iii) eluting said .sup.223Ra from said strong base anion exchange resin using a first mineral acid in an alcoholic aqueous solution to give a first eluted .sup.223Ra solution; iv) loading the .sup.223Ra of the first eluted .sup.223Ra solution onto a strong acid cation exchange resin; and v) eluting the .sup.223Ra from said strong acid cation exchange resin using a second mineral acid in aqueous solution to provide a second eluted solution. The invention additionally provides products of corresponding purity and/or products obtained or obtainable by such a method.

Methods for purifying .sup.89Zr are provided, .sup.89Zr compositions are provided, isotope compositions are provided that can include: a radio isotope and a nanoparticle, and methods for radio labeling monoclonal antibodies are provided.

The present invention relates to conjugates including a chelating moiety of a metal complex thereof and a therapeutic or targeting moiety, methods for their production, and uses thereof.

This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.

This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.